Leukaemia Drug Trial: UK Milestone | Cancer Research
- A recent UK-wide trial suggests a new, chemotherapy-free approach to treating chronic lymphocytic leukemia (CLL) could substantially improve patient outcomes.
- The study involved 786 previously untreated CLL patients.
- After five years,94% of patients receiving the combined ibrutinib and venetoclax therapy were alive with no disease progression.
A groundbreaking UK trial signals a major shift in leukemia treatment. Chronic lymphocytic leukemia (CLL) patients are experiencing considerably improved outcomes with a chemotherapy-free approach. The Flair trial reveals that a combination of targeted drugs, ibrutinib and venetoclax, leads to higher survival rates and is better tolerated than customary chemotherapy. Results detailed in the New England Journal of Medicine demonstrate that 94% of patients in the combined drug therapy group were alive after five years with no disease progression. Furthermore, 66% showed no detectable cancer after two years. News Directory 3 reports on this crucial research. This new approach offers hope for a less toxic and more effective way to treat leukemia. Discover what’s next in personalized cancer treatment.
Chemotherapy-Free Approach Shows Promise in Leukemia treatment
Updated june 16, 2025
A recent UK-wide trial suggests a new, chemotherapy-free approach to treating chronic lymphocytic leukemia (CLL) could substantially improve patient outcomes. The Flair trial, conducted across 96 cancer centers in the UK, explored the effectiveness of targeted cancer drugs as an alternative to standard chemotherapy for CLL, the most common form of leukemia in adults.
The study involved 786 previously untreated CLL patients. Participants were randomly assigned to receive either standard chemotherapy,the targeted drug ibrutinib alone,or a combination of ibrutinib and venetoclax.treatment was guided by personalized blood tests to monitor individual responses.
After five years,94% of patients receiving the combined ibrutinib and venetoclax therapy were alive with no disease progression. this contrasts with 79% for those treated with ibrutinib alone and 58% for those receiving standard chemotherapy. The findings were published in the New England Journal of Medicine and presented at the European Haematology Association congress in Milan, Italy.
furthermore, after two years, 66% of patients on the combined drug regimen showed no detectable cancer in their bone marrow, compared to none of those on ibrutinib alone and 48% on chemotherapy. Experts also noted that the combined-drug regimen was better tolerated than customary treatments.
Ibrutinib functions as a cancer growth blocker,disrupting signals that cancer cells use to divide and grow. Venetoclax targets a protein found in CLL cells, inhibiting its function.
Catherine Whitfield, 63, of Farnley, West Yorkshire, diagnosed with CLL in 2018, participated in the trial. “After three years of treatment, I am still MRD negative – that means no cancer cells,” she said.
Flair trial is a milestone.We have shown that a chemotherapy-free approach can be not only more effective but also more tolerable for patients.
The results show we can provide kinder, more targeted treatment for chronic lymphocytic leukaemia, which gives people with CLL more precious time with their loved ones.
What’s next
Researchers hope these findings will pave the way for new, less toxic treatment options for leukemia and other blood cancers, moving toward more personalized medicine approaches.